Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
van Hout, B.
1056  Ergebnisse:
Personensuche X
?
1

P60 A New Online Tool for Valuing Health States: Eliciting ..:

Schneider, P ; van Hout, B ; Heisen, M..
Value in Health.  25 (2022)  1 - p. S13 , 2022
Link: https://doi.org/10.1016/..
 
?
2

PCR28 The OPUF Tool: A New Type of Online Survey for Creati..:

Schneider, P ; Brazier, JE ; Devlin, N.
Value in Health.  25 (2022)  7 - p. S546 , 2022
Link: https://doi.org/10.1016/..
 
?
3

P.0350 Preference study in childhood autism spectrum disord..:

Hartl, K. ; Durno, N. ; Schmid, R....
European Neuropsychopharmacology.  53 (2021)  - p. S254-S255 , 2021
Link: https://doi.org/10.1016/..
 
?
4

P.0649 Preference Study in Childhood Autism Spectrum Disord..:

Zormpas, E. ; Durno, N. ; Schmid, R....
European Neuropsychopharmacology.  53 (2021)  - p. S478 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Cost-effectiveness of evolocumab in patients with familial ..:

Descamps, O.S. ; Van Hout, B. ; Lindgren, P....
Atherosclerosis.  315 (2020)  - p. e36 , 2020
Link: https://doi.org/10.1016/..
 
?
6

What potential risk reduction could be achieved with evoloc..:

Ray, K.K ; Bridges, I ; Bruckert, E...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
7

Additive predictive power of the CHA2DS2-VASc and HAS-BLED ..:

Morrone, D ; Kroep, S ; Ricci, F...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
8

Does Evolocumab use in Europe match 2019 ESC/EAS lipid guid..:

Ray, K.K ; Bruckert, E ; Van Hout, B...
European Heart Journal.  41 (2020)  Supplement_2 - p. , 2020
Link: https://doi.org/10.1093/..
 
?
9

PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC C..:

Lindgren, P. ; Hagström, E. ; van Hout, B....
Value in Health.  22 (2019)  - p. S548 , 2019
Link: https://doi.org/10.1016/..
 
?
10

P654Effectiveness of evolocumab for patients with familial ..:

Ray, K K ; Schoonen, M ; Annemans, L...
European Heart Journal.  40 (2019)  Supplement_1 - p. , 2019
Link: https://doi.org/10.1093/..
 
?
11

Deep Vein Thrombosis in Europe—Health-Related Quality of Li..:

Monreal, M. ; Agnelli, G. ; Chuang, L. H....
Clinical and Applied Thrombosis/Hemostasis.  25 (2019)  - p. 107602961988394 , 2019
Link: https://doi.org/10.1177/..
 
?
12

MS2 AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE C..:

Diakite, I. ; Lin, V.W. ; Klijn, S....
Value in Health.  22 (2019)  - p. S41 , 2019
Link: https://doi.org/10.1016/..
 
?
13

P1225Cost-effectiveness of evolocumab in patients with high..:

Lindgren, P ; Hagstrom, E ; Van Hout, B...
European Heart Journal.  40 (2019)  Supplement_1 - p. , 2019
Link: https://doi.org/10.1093/..
 
?
14

Deep-vein thrombosis in Europe — Burden of illness in relat..:

Chuang, L.H. ; van Hout, B. ; Cohen, A.T....
Thrombosis Research.  170 (2018)  - p. 165-174 , 2018
Link: https://doi.org/10.1016/..
 
?
15

P1699Characteristics of patients prescribed Evolocumab in E..:

Ray, K ; Bruckert, E ; Annemans, L...
European Heart Journal.  39 (2018)  suppl_1 - p. , 2018
Link: https://doi.org/10.1093/..
 
1-15